SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate

SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension studyWell-demonstrated...

Related Keywords

United States ,United Kingdom ,Australia ,Switzerland ,Canada ,Waltham ,Leicestershire ,Americans ,American ,Lissa Pavluk ,Caroline Baumal ,Meredith Kaya ,Lancet Glob Health ,American Academy Of Ophthalmology ,Linkedin ,Exchange Commission ,Apellis Pharmaceuticals Inc ,Research Group ,Nasdaq ,Exchange Commission On ,Twitter ,American Academy ,Term Extension ,Geographic Atrophy ,Safety Information ,Retinal Detachments ,Vascular Endothelial Growth Factor ,Prescribing Information ,Private Securities Litigation Reform Act ,Apelli Annual Report ,Nasdaq Apls ,Apellis Pharmaceuticals ,Nc ,